This study will shed light on the understanding of FLCN/FNIP1/FNIP2/AMPK function and the downstream target genes and signaling pathways that are important in tumorigenesis, providing insight into therapeutic targets for treatment of renal tumors that develop in BHD syndrome and translocation RCC. This evidence concerns the gene FLCN and Birt-Hogg-Dubé syndrome.